Sevelamer hydrochloride – new approaches in the treatment of chronic kidney disease related hyperphosphatemia

Abstract:

Disturbances of mineral metabolism are frequent in chronic kidney disease patients. Hyperphosphatemia is very common in progressive chronic kidney disease, esspecially in the end-stage renal disease. The treatment of hyperphosphatemia is very important because of its influence on morbidity and mortality of end-stage renal disease patients. Hyperphosphatemia is an independent predictor of mortality as it determines higher cardiovascular mortality in this patient population predominantly because of vascular calcifications. The treatment of hyperphosphatemia using the phosphate binder which does not containing either calcium or aluminium is benefitial as it reduces incidence of vascular calcifications, also reducing cardiovascular morbidity and mortality of uremic patients.

Key words:
hyperphosphatemia, cardiovascular mortality, vascular calcifications, sevelamer hydrochloride